


## Terameprocol

<b>Cat. No.:</b>	HY-10447		
<b>CAS No.:</b>	24150-24-1		
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>30</sub> O <sub>4</sub>		
<b>Molecular Weight:</b>	358.47		
<b>Target:</b>	Lipoxygenase		
<b>Pathway:</b>	Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (278.96 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.7896 mL	13.9482 mL	27.8963 mL
	5 mM	0.5579 mL	2.7896 mL	5.5793 mL
	10 mM	0.2790 mL	1.3948 mL	2.7896 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Terameprocol is a synthetic derivative of Nordihydroguaiaretic acid and a non-selective lipoxygenase inhibitor. Terameprocol has antiviral and antitumor effects<sup>[1][2][3]</sup>.

### REFERENCES

- [1]. Hwu JR, et al. Antiviral activities of methylated nordihydroguaiaretic acids. 1. Synthesis, structure identification, and inhibition of tat-regulated HIV transactivation. *J Med Chem.* 1998 Jul 30;41(16):2994-3000.
- [2]. Chen H, et al. Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. *J Med Chem.* 1998 Jul 30;41(16):3001-7.
- [3]. Park R, et al. Systemic treatment with tetra-O-methyl nordihydroguaiaretic acid suppresses the growth of human xenograft tumors. *Clin Cancer Res.* 2005 Jun 15;11(12):4601-9.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA